Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 19Terminated 8Unknown 7Recruiting 6Withdrawn 3Not yet recruiting 3Active not recruiting 2

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1Plasma cell 1Gynecologic 1

Conditions

Breast Neoplasms 28Carcinoma, Non-Small-Cell Lung 20Triple Negative Breast Neoplasms 9Ovarian Neoplasms 8Lung Neoplasms 8Uterine Cervical Neoplasms 6Adenocarcinoma of Lung 6Neoplasms 5Neoplasm Metastasis 5Esophageal Neoplasms 5Carcinoma, Ovarian Epithelial 4Stomach Neoplasms 3Recurrence 3Prostatic Neoplasms 3Esophageal Squamous Cell Carcinoma 3Urinary Bladder Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Platinum-Refractory Fallopian Tube Carcinoma 2Pancreatic Neoplasms 2Head and Neck Neoplasms 2Fallopian Tube Neoplasms 2Adenocarcinoma, Bronchiolo-Alveolar 2Unspecified Adult Solid Tumor, Protocol Specific 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Solid Tumors 1Small Cell Lung Carcinoma 1Sarcoma 1Recurrent High Grade Uterine Cancer 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1

Interventions

Dexamethasone 14Rituximab 6Cytarabine 5venetoclax 4Lenalidomide 4Bortezomib 4Bendamustine Hydrochloride 4selinexor 3pomalidomide 3pembrolizumab 3ibrutinib 3fludarabine 3carfilzomib 3Paclitaxel 3Gemcitabine 3Drug Therapy 3Cyclophosphamide 3Calcium Dobesilate 3ixazomib 2gilteritinib 2fludarabine phosphate 2elotuzumab 2daratumumab 2belinostat 2Tablets 2Surveys and Questionnaires 2Panobinostat 2Oxaliplatin 2Granulocyte Colony-Stimulating Factor 2Etoposide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × Recurrence × Paclitaxel × Clear all
NCT03361319 2020-11-24

N3

Royal Marsden NHS Foundation Trust

Phase 1/2 Withdrawn
Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Recurrence

NCT04561817 2020-10-06

To Evaluate the Safety and Efficacy of Ipatasertib (GDC-0068) in Combination With Paclitaxel in Platinum-resistant Recurrent Epithelial Ovarian Cancer

Icahn School of Medicine at Mount Sinai

Phase 2 Withdrawn
Gynecologic

Ovarian Neoplasms, Recurrence

NCT02985333 2018-05-14

Paclitaxel,Cyclophosphamide and Dexamethasone for Relapsed or Refractory Multiple Myeloma

Sun Yat-sen University

Phase 2 Withdrawn
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡